Warning: Aggressive Kratom & 7-OH Marketing Fuels Dependency Concerns, Heightening Regulatory Scrutiny

Brian Setzer's experience highlights a growing problem: aggressive marketing of highly concentrated kratom and 7-hydroxymitragynine (7-OH) products, often sold as 'tonics' or 'shots,' is leading to dependency issues and consumer confusion.

• No immediate legal status changes, but aggressive marketing of high-concentration products (especially 7-OH) is increasing regulatory scrutiny, potentially leading to future reclassification (e.g., FDA's 2025 recommendation for 7-OH as Schedule I).
• Increased risk of payment processor instability and account closures due to heightened regulatory attention on product marketing and dependency concerns.
• While no direct shipping warnings are issued, potential future reclassification of 7-OH products could severely impact logistics and distribution.

Source: Kratom Science via Sentinel Newsroom